---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-079600"
form_type: "8-K"
ticker: "GRTX"
cik: "0001563577"
company_name: "Galera Therapeutics, Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:08:19.979484+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galera reports FY2023 net loss $59.1M; avasopasem NDA rejected; strategic review may lead to dissolution

## Summary
- FY2023 net loss $59.1M ($1.33/sh); Q4 net loss $5.6M ($0.10/sh); cash $18.3M as of Dec 31, 2023.
- Cash and equivalents $18.3M at year-end; expected to fund operations into Q2 2025.
- FDA issued CRL for avasopasem NDA in Aug 2023; requires additional Phase 3 trial for resubmission.
- Halted GRECO-2 (pancreatic) and GRECO-1 (NSCLC) trials after futility; workforce reduced 70% in Aug 2023.
- Engaged Stifel to review strategic alternatives; CEO notes process could lead to dissolution.

## SEC filing metadata
- accession: 0001193125-24-079600
- form_type: 8-K
- ticker: GRTX
- cik: 0001563577
- company_name: Galera Therapeutics, Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/0001193125-24-079600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/d816795d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-079600
- JSON: https://secwatch.observer/filing/0001193125-24-079600.json
- Plain text: https://secwatch.observer/filing/0001193125-24-079600.txt

## Key facts
- Earnings Releases
  Galera Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
  - Period: the fourth quarter and year ended December 31, 2023
  - Result: reported results
  source text: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
  evidence_url: https://www.sec.gov/Archives/edgar/data/1563577/000119312524079600/0001193125-24-079600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.